Disease Information

General Information of the Disease (ID: DIS00542)

• Name: Esophageal cancer
• ICD: ICD-11: 2B70

Type(s) of Resistant Mechanism of This Disease

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Cisplatin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Insulin-like growth factor 1 receptor (IGF1R) [1]

• Metabolic Type: Amino acid metabolism
• Resistant Disease: Esophageal squamous cell carcinoma [ICD-11: 2B70.3]
• Resistant Drug: Cisplatin
• Molecule Alteration: Expression; Up-regulation

Differential expression of the molecule in resistant disease

• Classification of Disease: Esophageal cancer [ICD-11: 2B70]
• The Specified Disease: Esophageal squamous cell carcinoma
• The Studied Tissue: Blood
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 2.36E-03; Fold-change: 1.79E-01; Z-score: 3.19E+00
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: OSCC cells; Esophagus; Homo sapiens (Human); CVCL_KR33
• Experiment for Molecule Alteration: qRT-PCR; Western blot analysis
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: Herein, we found that the abnormal IGF1R pathway is a potential target for OSCC therapy. Under low-oxygen conditions, IGF1R induces DDP resistance by enhancing ASS1 and PYCR1 expression to promote arginine and proline metabolism. Combining the IGF1R inhibitor linsitinib and DDP led to synergistic effects on inhibiting cell proliferation in vitro and in vivo.

References

• Ref 1: Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia. J Exp Clin Cancer Res. 2023 Mar 28;42(1):73.